Monoclonal antibody
(antithrombotic).
Antiplatelet agent:
Prevention of ischaemic cardiac complications
in patients undergoing percutaneous coronary
intervention
Short-term prevention of myocardial infarction
in patients with unstable angina not responding
to treatment or awaiting percutaneous coronary
intervention.
This antithrombotic (MW = 47455 g/mol; CAS 143653-53-6; also known as Reopro?) consists of an immunoglobulin G1 Fab fragment from a chimeric human-murine monoclonal antibody directed against the human platelet glycoprotein IIb/IIIa receptor. Abciximab also facilitates the dispersal of newly formed platelet aggregates in vitro, by partially displacing fibrinogen from activated GPIIb/IIIareceptors. In vivo, abciximab may destabilize coronary thrombi by preventing aggregate formation and dispersing mural thrombi. Target(s): coagulation factor Xa, in presence of heparin; glycoprotein IIb/IIIa receptor.
Potentially hazardous interactions with other drugs
Heparin, anticoagulants, antiplatelets and
thrombolytics: increased risk of bleeding.
Following IV administration, abciximab rapidly binds
to the platelet GPIIb/IIIa receptors, and remains in the
circulation for 15 days or more in a platelet-bound state.
Metabolism is via proteolytic cleavage
